Does dose modification affect efficacy of first-line pazopanib in metastatic renal cell carcinoma?

被引：0
|
作者：
Grassi, Paolo
Procopio, Giuseppe
Ratta, Raffaele
Porcu, Luca
Martinetti, Antonia
Mennitto, Alessia
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.512
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
512
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib
    Kim, Myung Soo
    Chung, Ho Seok
    Hwang, Eu Chang
    Jung, Seung Il
    Kwon, Dong Deuk
    Hwang, Jun Eul
    Bae, Woo Kyun
    Park, Jae Young
    Jeong, Chang Wook
    Kwak, Cheol
    Song, Cheryn
    Seo, Seong Il
    Byun, Seok-Soo
    Hong, Sung-Hoo
    Chung, Jinsoo
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2018, 33 (51)
  • [22] First line pazopanib in poor risk patients with metastatic renal cell carcinoma
    Staehler, M.
    Panic, A.
    Merling, M.
    Vannier, C.
    Herrmann, E.
    Hogrefe, C.
    Potthoff, K.
    Gruenwald, V
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 203 - 203
  • [23] Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma
    Qin, Shu-Kui
    Jin, Jie
    Guo, Jun
    Wang, Jin-Wan
    Zhou, Fang-Dian
    Huang, Yi-Ran
    Ren, Xiu-Bao
    Ye, Ding-Wei
    Pan, Sharon
    Sajben, Peter
    Wang, Qiao
    [J]. FUTURE ONCOLOGY, 2018, 14 (18) : 1835 - 1845
  • [24] Tumor response criteria for assessing pazopanib first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Gupta, Shiva
    Kang, Hyunseon C.
    Sun, Jia
    Matrana, Marc R.
    Tannir, Nizar M.
    Choi, Haesun
    [J]. ABDOMINAL RADIOLOGY, 2020, 45 (06) : 1872 - 1882
  • [25] CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure
    Masini, C.
    Vitale, M. G.
    Maruzzo, M.
    Procopio, G.
    De Giorgi, U.
    Buti, S.
    Rossetti, S.
    Iacovelli, R.
    Guida, A.
    Atzori, F.
    Mucciarini, C.
    Cosmai, L.
    Vignani, F.
    Prati, G.
    Scagliarini, S.
    Berselli, A.
    Pinto, C.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 : 17 - 17
  • [26] CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure
    Masini, C.
    Vitale, M. G.
    Maruzzo, M.
    Procopio, G.
    De Giorgi, U.
    Buti, S.
    Rossetti, S.
    Iacovelli, R.
    Guida, A.
    Atzori, F.
    Mucciarini, C.
    Scagliarini, S.
    Vignani, F.
    Prati, G.
    Cosmai, L.
    Berselli, A.
    Pinto, C.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [27] Pazopanib for the First-Line Treatment of Patients with Advanced and/or Metastatic Renal Cell Carcinoma A NICE Single Technology Appraisal
    Kilonzo, Mary
    Hislop, Jenni
    Elders, Andrew
    Fraser, Cynthia
    Bissett, Donald
    McClinton, Samuel
    Mowatt, Graham
    Vale, Luke
    [J]. PHARMACOECONOMICS, 2013, 31 (01) : 15 - 24
  • [28] Pazopanib or Sunitinib? cost-utility analysis of pazopanib versus sunitinib in the first-line treatment of metastatic renal cell carcinoma in Jordan
    Al-Rabayah, Abeer A.
    Sawalha, Razan
    Al Froukh, Rawan Fawzi
    Al-Bawab, Rand
    Jaddoua, Saad M.
    [J]. JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH, 2021, 12 (04) : 566 - 573
  • [29] Tumor response criteria for assessing pazopanib first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Shiva Gupta
    Hyunseon C. Kang
    Jia Sun
    Marc R. Matrana
    Nizar M. Tannir
    Haesun Choi
    [J]. Abdominal Radiology, 2020, 45 : 1872 - 1882
  • [30] Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
    Vazquez, Sergio
    Leon, Luis
    Fernandez, Ovidio
    Lazaro, Martin
    Grande, Enrique
    Aparicio, Luis
    [J]. ADVANCES IN THERAPY, 2012, 29 (03) : 202 - 217
12345